PMNNasdaqPharmaceutical PreparationsFiscal year ends December 31

ProMIS Neurosciences Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$8.23+0.08 (+0.98%)

Close on Oct 19, 2026

Market cap: $75.24M
P/E (TTM): –
Dividend yield: –

ProMIS Neurosciences Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Cash & Equivalents	6.12	13	13	5.88	17	0.81
Short-Term Investments	0.03	0.03	0.03	0.03	0.03	–
Cash & Short-Term Investments	6.15	13	13	5.91	17	0.81
Prepaid Expenses & Other	3.03	5.59	0.99	1.00	0.74	–
Total Current Assets	9.18	19	14	6.90	18	–
Property, Plant & Equipment	–	–	–	0.00	0.00	–
Gross Property, Plant & Equipment	–	–	–	0.08	0.08	–
Accumulated Depreciation	–	–	–	-0.08	-0.08	–
Intangible Assets	–	–	–	0.02	0.03	–
Total Assets	9.18	19	14	6.92	18	–
Accounts Payable	2.54	1.74	7.84	2.98	0.41	–
Accrued Expenses	7.87	0.48	1.51	3.44	0.52	–
Total Current Liabilities	10	2.22	9.35	6.41	0.93	–
Total Liabilities	10	2.42	9.87	8.27	12	–
Common Stock	–	–	–	–	0	–
Additional Paid-In Capital	130	108	98	79	68	–
Retained Earnings	-130	-91	-93	-80	-62	–
Comprehensive Income & Other	-0.37	-0.37	-0.37	-0.20	-0.19	–
Shareholders' Equity	-1.26	16	3.75	-1.35	5.66	-0.80
Total Equity	-1.26	16	3.75	-1.35	5.66	-0.80
Total Liabilities & Equity	9.18	19	14	6.92	18	–
Shares Outstanding(shares)	2.15	1.31	0.76	0.34	0.29	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -521.6%

Financial strength

Current ratio: 7.85
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 740.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.52
Dividend yield: –